28 November 2016
TopiVert, a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and eye, announced today that its Investigational New Drug (IND) application for the evaluation of TOP1630 ophthalmic solution as a treatment of patients with dry eye syndrome (DES) has been approved by the US Food and Drug Administration (FDA).
28 October 2016
GALWAY, Ireland, Oct. 28, 2016—4Tech Inc., a privately held clinical-stage company that is developingthe world’s first transcatheter device, TriCinch™, for repair of the Tricuspid heart valve, today announced that it has elected William (“Bill”) A. Hawkins as Chairman, effective immediately. Hawkins was previously Chairman and CEO of Medtronic from 2008—2011, which he joined in 2002 as Senior Vice President and President of Medtronic Vascular.
18 October 2016
Additional analyses of data from COLLECT – a clinical study of InDex Pharmaceuticals Holding AB’s (publ) lead drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis – was orally presented and met with great interest at the United European Gastroenterology Week (UEGW) 2016 in Vienna.
12 October 2016
Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announces the appointment of Paul Fry as Chief Financial Officer.
7 October 2016JenaValve Technology Appoints Veteran Medical Device Executive Greg Mirigian As Vice President of Research and Development
JenaValve Technology, Inc., a developer, manufacturer and marketer of differentiated heart-valve technology, and a company that is committed to making transcatheter aortic valve replacement (TAVR) available to the broadest spectrum of patients with aortic valve disease, today announced the appointment of veteran medical device executive Greg Mirigian as Vice President of Research and Development, effective immediately. Mirigian will be based in Irvine, Calif. at JenaValve’s corporate headquarters.